Johnson & Johnson (JNJ)
This Medical Giant's Stock Rebounds: A 15% Upside Is the Minimum
Johnson & Johnson NYSE: JNJ has struggled for the last year or two as the impacts of COVID-19 and the spin-off of Kenvue NYSE: KVUE work their way through the system. The takeaway from the Q2 earnings release is that organic growth is back in the picture.
Johnson & Johnson (JNJ) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson Posts Mixed Earnings, Shifts Full-Year Guidance
Johnson & Johnson (JNJ) reported mixed second-quarter results Wednesday, as one-time costs caused the company to miss profit estimates despite better-than-expected sales.
Johnson & Johnson (JNJ) Beats Q2 Earnings and Revenue Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.82 per share, beating the Zacks Consensus Estimate of $2.71 per share. This compares to earnings of $2.80 per share a year ago.
Johnson & Johnson's Q2 Earnings: Revenue And Profit Beat On Strong Pharma Sales, Annual Profit Outlook Lowered On M&A Costs
On Wednesday, Johnson & Johnson JNJ reported a second-quarter adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70.
Johnson & Johnson stock gets a lift from earnings beat, while outlook was mixed
Shares of Johnson & Johnson JNJ, +1.19% rose 1.1% in premarket trading Wednesday, after the drug maker beat second-quarter profit and sales expectations, while providing a mixed full-year outlook. Net income fell to $4.69 billion, or $1.93 a share, from $5.14 billion, or $2.05 a share, in the same period a year ago.
J&J beats Wall Street estimates on strong drug sales
Johnson & Johnson beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis drug Stelara.
Johnson & Johnson Earnings Are Coming. It Took Steps to Put Its Talc Issues Behind It.
ohnson & Johnson is expected to report earnings of $2.71 a share, down slightly from $2.80 from the same period a year ago.
Johnson & Johnson: Bullish Charts Signal Strong Setup Before Q2 Earnings
Johnson & Johnson JNJ is reporting its second-quarter earnings on Wednesday. Wall Street expects $2.7 in EPS and $22.3 billion in revenues as the company reports before market hours.
How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings
Johnson & Johnson JNJ will release its second-quarter financial results, before the opening bell on Wednesday, July 17.
MedTech To Drive Johnson & Johnson's Q2?
Johnson & Johnson stock (NYSE: JNJ) will report its Q2 2024 results on Wednesday, July 17. We expect the company to post revenue of $22.5 billion and earnings of $2.72 per share, broadly aligning with the consensus estimates of $22.4 billion and $2.71, respectively.
J&J (JNJ) Stock Before Q2 Earnings: To Buy or Not to Buy?
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
